




Ahead of the major bank earnings week, Wells Fargo’s Mike Mayo expects overall US bank earnings to rise 15% to 20% YoY. The growth outlook is supported by strong Wall Street trading revenues and robust commercial loan growth. With five of the six largest banks reporting within hours, the results are likely to meaningfully influence sector sentiment and near-term stock moves.
Into the print, this looks more like a quality-vs-beta event than a clean sector upgrade. The immediate upside should accrue to JPM and GS if markets revenue is broad, but that is the least durable driver and tends to mean-revert once volatility normalizes; the cleaner second-order beneficiary is WFC, where incremental commercial loan growth has more operating leverage to net interest income and fewer moving parts. BAC sits in the middle: decent upside if credit stays benign, but still vulnerable to deposit repricing if balance-sheet growth outpaces funding costs.
The main risk is confusing a good quarter with a better earnings power trend. If the upside comes from trading and reserve releases rather than higher core earning assets, the stocks can gap up and then fade over the next 1-3 months as investors refocus on NII trajectory, CET1, and buyback cadence. A durable rerating would require managements to raise full-year NII guidance or explicitly signal that loan growth is broad enough to offset deposit beta; absent that, this is likely a trading event, not a structural re-rate.
Contrarian view: the market may already be paying for the strong numbers in the highest-quality franchises, especially JPM and GS, while underappreciating relative upside in WFC if Main Street lending is truly inflecting. The consensus risk is over-weighting headline EPS and under-weighting the composition of earnings. If loan growth does not convert into better NII, or if credit costs tick up, the thesis breaks quickly and the post-earnings move should be faded.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment